MPM BioVentures
QuietFiled to raiseCambridge, MABiotech & pharma, Enterprise software, Medical devicesLast fund filed May 2022
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| MPM BioVentures 2022 | May 2022 | Indefinite | $351M | 45 |
| MPM ONCOLOGY INNOVATIONS FUND | July 2018 | $99M | $99M | 36 |
| MPM BIOVENTURES 2018 (B)Filed to raise in 2018, with no closing reported yet. | 2018 | $400M | $0 | 0 |
| MPM BIOVENTURES 2018Filed to raise in 2018, with no closing reported yet. | 2018 | $400M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
5 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Ansbert Gadicke | Quiet | Biotech & pharma, Enterprise software | 7 |
Categories of MPM BioVentures’s own portfolio companies, based on 42 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of MPM BioVentures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Vida Ventures | 4 | Aktis Oncology, HotKnot Therapeutics, Orna Therapeutics Holdings, RECODE THERAPEUTICS |
| Abingworth Bioventures | 2 | CHIASMA, PROTEON THERAPEUTICS |
| Versant Venture Capital | 2 | Aligos Therapeutics, Firefly Bio |
| Aditum Bio |
| MPM Bio 2014 NVS Strategic Fund |
| June 2014 |
| $23M |
| $23M |
| 1 |
| MPM BioVentures 2014 | June 2014 | $347M | $347M | 94 |
| 0 |
| Edward HurwitzNot on the current fund | Quiet | Biotech & pharma | 7 | 0 |
| James ScopaNot on the current fund | Quiet | Biotech & pharma | 8 | 0 |
| Luke Evnin | Quiet | Biotech & pharma | 13 | 0 |
| Todd FoleyNot on the current fund | Quiet | Biotech & pharma, Enterprise software, Medical devices | 15 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 1 |
| Semma Therapeutics |
| Advent Life Sciences | 1 | IDUN PHARMACEUTICALS |
| Atlas Venture | 1 | Dyne Therapeutics |
| Bioluminescence Ventures | 1 | RECODE THERAPEUTICS |
| Catalio Capital Management | 1 | NextPoint Therapeutics |
| Cortado Ventures | 1 | MOAT BIOTECHNOLOGY |
| Cure Ventures | 1 | Entrada Therapeutics |
| DCVC | 1 | Umoja Biopharma |
| DigiTx Partners | 1 | DigiTx Partners |
| NEA | 1 | RHYTHM METABOLIC |
| Polaris Partners | 1 | Crossbow Therapeutics |
| Sands Capital Ventures | 1 | DiCE MOLECULES HOLDINGS |
A shared board seat: a company where filings name a MPM BioVentures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.